Live Breaking News & Updates on Global fund expert review panel for diagnostics

Stay informed with the latest breaking news from Global fund expert review panel for diagnostics on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Global fund expert review panel for diagnostics and stay connected to the pulse of your community

NEXT GENERATION TB TEST DEVELOPED WITH ELLUME TECHNOLOGY RECEIVES APPROVAL FROM KEY GLOBAL REVIEW PANEL FOR USE IN MORE THAN 100 LOW-RESOURCE, HIGH BURDEN COUNTRIES

/PRNewswire/ -- Digital diagnostics company Ellume today announced that the QIAreach QuantiFERON-TB test (QIAreach QFT), developed with Ellume technology, and...

United-states , Australia , Brisbane , Queensland , Australian , America , Patrick-condren , Sean-parsons , Global-fund , Tb-partnership-global-drug-facility , Global-fund-expert-review-panel-for-diagnostics , World-health-organization

Statement by the Malaria Policy Advisory Group on the urgent need to address the high prevalence of pfhrp2/3 gene deletions in the Horn of Africa and beyond - Ethiopia

Statement by the Malaria Policy Advisory Group on the urgent need to address the high prevalence of pfhrp2/3 gene deletions in the Horn of Africa and beyond
Format
Malaria rapid diagnostic tests (RDTs) have transformed malaria control, enabling better targeting of treatment and improved surveillance. Globally, 2.7 billion RDTs for malaria were sold between 2010–2019, the majority distributed in Sub-Saharan Africa to diagnose P. falciparum (Pf) infection by targeting one of its antigens, histidine-rich protein 2 (HRP2). This current cornerstone of P. falciparum diagnosis is under serious threat as a result of the emergence of parasites not expressing the HRP2 protein due to mutations in the genes that encode it. Consequently, HPR2-based RDTs are unable to detect infections with such parasites, putting patients at risk of misdiagnosis, significant morbidity and potentially death. These gene deletions were first reported a decade ago in Peru and were subsequently found in neighbouring countries. This lead to a reversion to microscopy as the primary diagnostic tool in this region. Over the past 6 years, an increasing number of African and Asian countries where diagnosis is heavily reliant on HRP2-based RDTs have reported histidine-rich protein 2 and 3 gene (

South-sudan , Peru , Djibouti , Sudan , Ethiopia , Somalia , Eritrea , Global-fund-expert-review-panel-for-diagnostics , Malaria-policy-advisory-group , Sub-saharan-africa , Global-fund-expert-review-panel

Statement on urgent need to address high prevalence of pfhrp2/3 gene deletions in Horn of Africa and beyond

Date Time
Share
Statement on urgent need to address high prevalence of pfhrp2/3 gene deletions in Horn of Africa and beyond
Malaria rapid diagnostic tests (RDTs) have transformed malaria control, enabling better targeting of treatment and improved surveillance. Globally, 2.7 billion RDTs for malaria were sold between 2010–2019, the majority distributed in Sub-Saharan Africa to diagnose P. falciparum (Pf) infection by targeting one of its antigens, histidine-rich protein 2 (HRP2). This current cornerstone of P. falciparum diagnosis is under serious threat as a result of the emergence of parasites not expressing the HRP2 protein due to mutations in the genes that encode it. Consequently, HPR2-based RDTs are unable to detect infections with such parasites, putting patients at risk of misdiagnosis, significant morbidity and potentially death. These gene deletions were first reported a decade ago in Peru and were subsequently found in neighbouring countries. This lead to a reversion to microscopy as the primary diagnostic tool in this region. Over the past 6 years, an increasing number of African and Asian countries where diagnosis is heavily reliant on HRP2-based RDTs have reported histidine-rich protein 2 and 3 gene (pfhrp2/3) deletions, raising the threat to a new level.

South-sudan , Peru , Djibouti , Sudan , Ethiopia , Somalia , Eritrea , Global-fund-expert-review-panel-for-diagnostics , Malaria-policy-advisory-group , Sub-saharan-africa , Global-fund-expert-review-panel

Statement by the Malaria Policy Advisory Group on the urgent need to address the high prevalence of pfhrp2/3 gene deletions in the Horn of Africa and beyond

Statement by the Malaria Policy Advisory Group on the urgent need to address the high prevalence of pfhrp2/3 gene deletions in the Horn of Africa and beyond
Statement by the Malaria Policy Advisory Group on the urgent need to address the high prevalence of pfhrp2/3 gene deletions in the Horn of Africa and beyond
28 May 2021
Reading time:
Malaria rapid diagnostic tests (RDTs) have transformed malaria control, enabling better targeting of treatment and improved surveillance. Globally, 2.7 billion RDTs for malaria were sold between 2010–2019, the majority distributed in Sub-Saharan
Africa to diagnose
P. falciparum (Pf) infection by targeting one of its antigens, histidine-rich protein 2 (HRP2). This current cornerstone of

South-sudan , Peru , Djibouti , Sudan , Ethiopia , Somalia , Eritrea , Health-organization , Global-fund-expert-review-panel-for-diagnostics , World-health-organization , Malaria-policy-advisory-group